IntroductIon
The full Guideline for Bronchiectasis in Adults is published in Thorax. 1 The key features of the guideline are highlighted in a short article published to accompany the full guideline. 2 The following is a summary of the recommendations and good practice points and includes all figures 1-5 and tables 1-7. The sections referred to in the summary refer to the full guideline. Table 1 provides a summary of overall management.
bAckground This guideline refers to the investigation and management of patients with symptoms of persistent or recurrent bronchial sepsis related to irreversibly damaged and dilated bronchi, namely clinical bronchiectasis. It does not cover the management of cystic fibrosis (CF), and for the purposes of the guideline, 'bronchiectasis' is synonymous with the term 'non-CF bronchiectasis'. Likewise, it does not focus on traction bronchiectasis secondary to other lung pathologies, particularly the interstitial lung diseases, as the bronchiectasis is commonly asymptomatic.
For guidance on treatment for patients with non-tuberculous mycobacteria and bronchiectasis, please refer to the BTS Guideline on the management of non-tuberculous mycobacterial pulmonary disease. 3 tArget AudIence for the guIdelIne This guideline is aimed at all healthcare practitioners who are involved in the care of patients with bronchiectasis: this will include primary care clinicians (general practitioners, practice and district nurses) and hospital specialist teams in infectious disease, respiratory medicine (respiratory nurse specialists, respiratory physiotherapists, pharmacists, physicians and surgeons), microbiologists, and radiologists.
AreAs covered by the guIdelIne
This guideline covers adults. The following patient groups not covered by this guideline are patients with CF bronchiectasis and children up to and including 15 years of age.
Methodology
This guideline is based on the best available evidence. The methodology used to write the guideline adheres strictly to the criteria as set by the Appraisal of Guidelines, Research and Evaluation collaboration, which is available online ( www. agreetrust. org/ resource-centre/ agree-ii/). The British Thoracic Society Standards of Care Committee guideline production manual is also available online (http://www. britthoracic. org. uk/ guidelines-and-qualitystandards/).
clInIcAl questIons And lIterAture seArch Clinical questions were structured in the PICO (Patient, Intervention, Control, Outcome) format (see full guideline, online appendix 1 1 ) to define the scope of the guideline and inform the literature search.
Systematic electronic database searches were conducted in order to identify potentially relevant studies for inclusion in the guideline. For each topic area, the following databases were searched: Ovid MEDLINE (including MEDLINE In Process), Ovid EMBASE and the Cochrane Library (including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects) from 1980.
The searches were first run in June 2014 and updated in June 2016 (see full guideline, appendix 2 for search strategy). Searches included a combination of indexed terms and free text terms and were limited to English language publications only. The initial search identified 3848 potentialabstracts and the second search 1021 abstracts.
consIdered judgeMent And grAdIng of evIdence The Guideline Development Group used the evidence tables to judge the body of evidence and grade recommendations for this guideline (see full guideline online appendix 3). An evidence level was assigned to each relevant study using Scottish intercollegiate Open access Figure 2 Stepwise management.
Antibiotics are used to treat exacerbations that present with an acute detrioration (usually over several days) with worsening local symptoms (cough,increased sputum volume or change of viscoisity, increased sputum purulence with or without increasing wheeze, breathlessness, haemoptypsis) and/ or systemic upset. The flow diagram refers to three or more annual exacerbations. Guideline Network (SIGN) methodology (table 2) , and where evidence was lacking to answer the formulated clinical questions, expert opinions were obtained through consensus. The following were considered in grading of the recommendations:
• The available volume of the body of evidence.
• How applicable the obtained evidence was in making recommendations for the defined target audience of this guideline.
• Whether the evidence was generalisable to the target population for the guideline.
• Whether there was a clear consistency in the evidence obtained to support recommendations.
• What the implications of recommendations would be on clinical practice in terms of resources and skilled expertise.
• Cost-effectiveness was not reviewed in detail as in-depth economic analysis of recommendations falls beyond the scope of this guideline. Recommendations were graded from A to D as indicated by the strength of the evidence as shown in table 3. In line with SIGN guidance, 'minus' evidence was considered in context, but in the absence of other 'plus' supporting evidence, it was discussed among the Guideline Development Group (GDG) regarding that point and any recommendation hence made Open access was grade D. Important practical points lacking any research evidence nor likely to be research evidence in the future were highlighted as 'Good Practice Points'.
drAftIng the guIdelIne The GDG corresponded regularly by email and meetings of the co-chairs subgroup and full group were held in January, May and June 2014; January, May, September and December 2015; January, April and December 2016; January and November 2017. A number of teleconferences were also held. The BTS Standards of Care Committee (SOCC) reviewed the draft guideline in November 2017. The draft guideline was made available online March-April 2018 for public consultation and circulated to all the relevant stakeholders. The BTS SOCC re-reviewed the revised draft guideline in June 2018 and final SOCC approval granted in July 2018.
This BTS Guideline will be reviewed within 5 years from the publication date.
declArAtIons of Interest
All members of the Guideline Group made declarations of interest in line with BTS Policy and further details can be obtained on request from BTS. Guideline Group members are listed in online appendix 1 to the full guideline. Management in exacerbations-see figure 4.
Open access
Stepwise management See (figure 2) Antibiotic treatment for exacerbations-see table 6 Management of rhinosinusitis-see figure 5 Management of ABPA.
Offer oral corticosteroid to patients with active ABPA. An initial dose of 0.5 mg/kg/day, for 2 weeks is recommended.
Wean steroids according to clinical response and serum IgE levels. Consider itraconazole as a steroid-sparing agent for patients dependent on oral corticosteroids where difficulty in weaning is experienced. Monitor with total IgE level to assess treatment response.
The deteriorating patient A deteriorating patient is defined as significant and prolonged deterioration of symptoms, unexpected increased frequency or severity of exacerbations, frequent hospital admissions, early relapse after treatment of an exacerbation or rapid decline in lung function. A management plan to help in dealing with these patients is shown in figure 1. In whom should the diagnosis of bronchiectasis be suspected? Recommendations ► Consider investigation for bronchiectasis in patients with persistent production of mucopurulent or purulent sputum particularly with relevant associated risk factors (D). ► Consider investigation for bronchiectasis in patients with rheumatoid arthritis if they have symptoms of chronic productive cough or recurrent chest infections (C). ► Consider investigation for bronchiectasis in patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations (two or more annually) and a previous positive sputum culture for Pseudomonas aeruginosa while stable (B). ► Consider investigation for bronchiectasis in patients with inflammatory bowel disease and chronic productive cough (C).
Open access Open access ✔ Long-term antibiotic choice is complex and has to take into account factors such as tolerance, allergies and sensitivity; therefore, in some circumstances, other long-term antibiotic regimens may be appropriate (see full guideline appendix 3). ✔ Perform a suitable challenge test when stable before starting inhaled antibiotics (see full guideline appendix 2). ✔ Consider cyclical intravenous antibiotics in patients with repeated infections (≥5/year) despite other treatments. ✔ Alternative inhaled/nebulised agents may become licensed as international studies are completed. ✔ For patients receiving long-term prophylactic oral antibiotics, the preferred option is to remain on the same antibiotic as opposed to monthly rotation of antibiotics. If there is a subsequent lack of efficacy, the antibiotic can be changed guided by sensitivity results.
Research recommendations
Long-term randomised controlled trials of oral and inhaled antibiotics are needed to assess their efficacy and safety in patients with bronchiectasis who have frequent respiratory tract infections with recurrent P. aeruginosa infection or other potential pathogenic micro-organisms.
does long-term bronchodilator treatment improve outcomes for patients with bronchiectasis? Recommendations ► Use of bronchodilators in patients with bronchiectasis and coexisting COPD or asthma should follow the guideline recommendations for COPD or asthma (D). ► Offer a trial of long-acting bronchodilator therapy in patients with symptoms of significant breathlessness (D). ► Reversibility testing to beta-2 agonist or anticholinergic bronchodilators may help to identify patients with coexisting asthma, but there is no evidence to suggest that a response is required in order to benefit from bronchodilators (D).
pulmonary rehabilitation Recommendations ► Offer pulmonary rehabilitation to individuals who are functionally limited by shortness of breath (Modified Medical Research Council Dyspnoea Scale ≥1) (B). ► Consider the use of inspiratory muscle training in conjunction with conventional pulmonary rehabilitation to enhance the maintenance of the training effect (B). Good practice points ✔ Educate all individuals with bronchiectasis on the importance of an exercise training programme. ✔ Consider the 6 minute walk test (6MWT) and/or the incremental shuttle walking test (ISWT) when evaluating exercise capacity before/after pulmonary rehabilitation in bronchiectasis. Prior to this, practice tests should be carried out to eliminate any learning effect. ✔ Pulmonary rehabilitation providers should offer education sessions tailored to the needs of individuals with bronchiectasis (eg, airway clearance techniques, the pathophysiology of bronchiectasis and relevant inhaled therapy). ✔ Pulmonary rehabilitation exercise and education sessions should be provided by appropriately qualified healthcare practitioners. Further information on pulmonary rehabilitation is provided in the BTS Quality Standards for Pulmonary rehabilitation (https://www. brit-thoracic. org. uk/ standards-of-care/ quality-standards/ bts-pulmonary-rehabilitation-quality-standards/).
Research recommendation
The role of education, self-management plans and who delivers the pulmonary rehabilitation needs to be explored.
The role of pulmonary rehabilitation after exacerbations requiring hospital admission needs to be explored.
The incidence of cross-infection of respiratory pathogens in the group exercise setting should be investigated in the bronchiectasis population.
What is the role of surgery in managing bronchiectasis? Recommendations ► Consider lung resection in patients with localised disease whose symptoms are not controlled by medical treatment optimised by a bronchiectasis specialist (D). ► Offer multidisciplinary assessment, including a bronchiectasis physician, a thoracic surgeon and an experienced anaesthetist, of suitability for surgery and preoperative assessment of cardiopulmonary reserve post resection (D). Good practice point ✔ Consider nutritional support and preoperative pulmonary rehabilitation before surgical referral. should treatment of bronchiectasis be altered in the presence of comorbidities? Recommendations ► Consider a trial of inhaled and/or oral corticosteroids in patients with bronchiectasis and inflammatory bowel disease (D) ► Ensure optimal control of asthma and allergies in patients with both bronchiectasis and asthma (Grade D). ► Monitor patients with comorbid COPD and bronchiectasis as they are at higher risk of death (D). ► Patients with bronchiectasis and autoimmune conditions should be carefully assessed for autoimmune-related lung disease and often require long-term follow-up in a secondary care setting (D). ► Patients with bronchiectasis who require disease modifying antirheumatic drugs (DMARDs) or biologics for rheumatoid arthritis should be referred to a chest physician for further assessment before treatment is started (D).
Open access how should we monitor bronchiectasis? Recommendation ► All patients with bronchiectasis should undergo routine monitoring in order to identify disease progression, pathogen emergence and modify treatment where necessary (D). Good practice points ✔ Tailor the frequency of routine monitoring to the patient's disease severity (see table 7 ). ✔ Assess patients annually and more frequently in more severe disease. ✔ Perform pulse oximetry to screen for patients who may need blood gas analysis to detect respiratory failure. ✔ A baseline CXR may provide a useful comparator in the event of clinical deterioration.
Is there a role for microbiological sensitivity testing? Good practice points ✔ Antibiotic sensitivity testing can be used to determine if resistance develops to either acute or long-term antibiotic treatment. ✔ Where possible, treatment should be guided by antibiotic sensitivity results but is often empirical based on previous sputum bacteriology. ✔ Some patients with an infective exacerbation may respond to antibiotic treatment despite resistance to that drug in vitro. Antibiotics should only be changed if there is no clinical response. ✔ For those on long-term antibiotic treatment, there should be repeat sensitivity testing where there is a clinical concern regarding loss of efficacy with therapy.
Is there any evidence of cross-infection with pathogenic organisms (conventional bacteria and environmental mycobacteria)? Recommendation ► Individual or cohort segregation based on respiratory tract microbiology results is not routinely required for patients with bronchiectasis (D) Good practice points ✔ Good cross-infection prevention principles should be applied: seek advice on local policies. ✔ The transmissibility of P. aeruginosa in CF appears more common. In the case of shared facilities with patients with CF, the cross-infection guidelines for CF should prevail.
Large-scale robust data that confirm or refute the transmissibility of key pathogens such as P. aeruginosa and non-tuberculous mycobacteria are needed.
Larger multicentre studies with longitudinal assessment of transmissible strains in bronchiectasis are needed. Studies are needed for P. aeruginosa and non-tuberculous mycobacteria as these are associated with poorer outcomes. specialist versus non-specialist setting Good practice point ✔ Specialist clinics should be considered in patients requiring hospital follow-up.
What are the complications of bronchiectasis? Good practice points ✔ If haemoptysis 10 ml or less over a 24-hour period, treat with an appropriate oral antibiotic. If clinical deterioration, arrange emergency admission to hospital. ✔ Management of major haemoptysis should be multidisciplinary with involvement of respiratory physicians, interventional radiology and thoracic surgeons. Empirically treat patients with intravenous antibiotic therapy, based on their known microbiology, and consider adjunct treatment with tranexamic acid. Bronchial artery embolisation is the recommended firstline treatment if significant haemoptysis persists. 
